Cargando…

The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics

Membrane transporters play a fundamental role in the tissue distribution of endogenous compounds and xenobiotics and are major determinants of efficacy and side effects profiles. Polymorphisms within these drug transporters result in inter-individual variation in drug response, with some patients no...

Descripción completa

Detalles Bibliográficos
Autores principales: Yee, Sook Wah, Macdonald, Christian, Mitrovic, Darko, Zhou, Xujia, Koleske, Megan L., Yang, Jia, Silva, Dina Buitrago, Grimes, Patrick Rockefeller, Trinidad, Donovan, More, Swati S., Kachuri, Linda, Witte, John S., Delemotte, Lucie, Giacomini, Kathleen M., Coyote-Maestas, Willow
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274788/
https://www.ncbi.nlm.nih.gov/pubmed/37333090
http://dx.doi.org/10.1101/2023.06.06.543963
_version_ 1785059794895241216
author Yee, Sook Wah
Macdonald, Christian
Mitrovic, Darko
Zhou, Xujia
Koleske, Megan L.
Yang, Jia
Silva, Dina Buitrago
Grimes, Patrick Rockefeller
Trinidad, Donovan
More, Swati S.
Kachuri, Linda
Witte, John S.
Delemotte, Lucie
Giacomini, Kathleen M.
Coyote-Maestas, Willow
author_facet Yee, Sook Wah
Macdonald, Christian
Mitrovic, Darko
Zhou, Xujia
Koleske, Megan L.
Yang, Jia
Silva, Dina Buitrago
Grimes, Patrick Rockefeller
Trinidad, Donovan
More, Swati S.
Kachuri, Linda
Witte, John S.
Delemotte, Lucie
Giacomini, Kathleen M.
Coyote-Maestas, Willow
author_sort Yee, Sook Wah
collection PubMed
description Membrane transporters play a fundamental role in the tissue distribution of endogenous compounds and xenobiotics and are major determinants of efficacy and side effects profiles. Polymorphisms within these drug transporters result in inter-individual variation in drug response, with some patients not responding to the recommended dosage of drug whereas others experience catastrophic side effects. For example, variants within the major hepatic Human organic cation transporter OCT1 (SLC22A1) can change endogenous organic cations and many prescription drug levels. To understand how variants mechanistically impact drug uptake, we systematically study how all known and possible single missense and single amino acid deletion variants impact expression and substrate uptake of OCT1. We find that human variants primarily disrupt function via folding rather than substrate uptake. Our study revealed that the major determinants of folding reside in the first 300 amino acids, including the first 6 transmembrane domains and the extracellular domain (ECD) with a stabilizing and highly conserved stabilizing helical motif making key interactions between the ECD and transmembrane domains. Using the functional data combined with computational approaches, we determine and validate a structure-function model of OCT1s conformational ensemble without experimental structures. Using this model and molecular dynamic simulations of key mutants, we determine biophysical mechanisms for how specific human variants alter transport phenotypes. We identify differences in frequencies of reduced function alleles across populations with East Asians vs European populations having the lowest and highest frequency of reduced function variants, respectively. Mining human population databases reveals that reduced function alleles of OCT1 identified in this study associate significantly with high LDL cholesterol levels. Our general approach broadly applied could transform the landscape of precision medicine by producing a mechanistic basis for understanding the effects of human mutations on disease and drug response.
format Online
Article
Text
id pubmed-10274788
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-102747882023-06-17 The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics Yee, Sook Wah Macdonald, Christian Mitrovic, Darko Zhou, Xujia Koleske, Megan L. Yang, Jia Silva, Dina Buitrago Grimes, Patrick Rockefeller Trinidad, Donovan More, Swati S. Kachuri, Linda Witte, John S. Delemotte, Lucie Giacomini, Kathleen M. Coyote-Maestas, Willow bioRxiv Article Membrane transporters play a fundamental role in the tissue distribution of endogenous compounds and xenobiotics and are major determinants of efficacy and side effects profiles. Polymorphisms within these drug transporters result in inter-individual variation in drug response, with some patients not responding to the recommended dosage of drug whereas others experience catastrophic side effects. For example, variants within the major hepatic Human organic cation transporter OCT1 (SLC22A1) can change endogenous organic cations and many prescription drug levels. To understand how variants mechanistically impact drug uptake, we systematically study how all known and possible single missense and single amino acid deletion variants impact expression and substrate uptake of OCT1. We find that human variants primarily disrupt function via folding rather than substrate uptake. Our study revealed that the major determinants of folding reside in the first 300 amino acids, including the first 6 transmembrane domains and the extracellular domain (ECD) with a stabilizing and highly conserved stabilizing helical motif making key interactions between the ECD and transmembrane domains. Using the functional data combined with computational approaches, we determine and validate a structure-function model of OCT1s conformational ensemble without experimental structures. Using this model and molecular dynamic simulations of key mutants, we determine biophysical mechanisms for how specific human variants alter transport phenotypes. We identify differences in frequencies of reduced function alleles across populations with East Asians vs European populations having the lowest and highest frequency of reduced function variants, respectively. Mining human population databases reveals that reduced function alleles of OCT1 identified in this study associate significantly with high LDL cholesterol levels. Our general approach broadly applied could transform the landscape of precision medicine by producing a mechanistic basis for understanding the effects of human mutations on disease and drug response. Cold Spring Harbor Laboratory 2023-06-07 /pmc/articles/PMC10274788/ /pubmed/37333090 http://dx.doi.org/10.1101/2023.06.06.543963 Text en https://creativecommons.org/licenses/by-nc-nd/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.
spellingShingle Article
Yee, Sook Wah
Macdonald, Christian
Mitrovic, Darko
Zhou, Xujia
Koleske, Megan L.
Yang, Jia
Silva, Dina Buitrago
Grimes, Patrick Rockefeller
Trinidad, Donovan
More, Swati S.
Kachuri, Linda
Witte, John S.
Delemotte, Lucie
Giacomini, Kathleen M.
Coyote-Maestas, Willow
The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics
title The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics
title_full The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics
title_fullStr The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics
title_full_unstemmed The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics
title_short The full spectrum of OCT1 (SLC22A1) mutations bridges transporter biophysics to drug pharmacogenomics
title_sort full spectrum of oct1 (slc22a1) mutations bridges transporter biophysics to drug pharmacogenomics
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10274788/
https://www.ncbi.nlm.nih.gov/pubmed/37333090
http://dx.doi.org/10.1101/2023.06.06.543963
work_keys_str_mv AT yeesookwah thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT macdonaldchristian thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT mitrovicdarko thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT zhouxujia thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT koleskemeganl thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT yangjia thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT silvadinabuitrago thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT grimespatrickrockefeller thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT trinidaddonovan thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT moreswatis thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT kachurilinda thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT wittejohns thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT delemottelucie thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT giacominikathleenm thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT coyotemaestaswillow thefullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT yeesookwah fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT macdonaldchristian fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT mitrovicdarko fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT zhouxujia fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT koleskemeganl fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT yangjia fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT silvadinabuitrago fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT grimespatrickrockefeller fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT trinidaddonovan fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT moreswatis fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT kachurilinda fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT wittejohns fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT delemottelucie fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT giacominikathleenm fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics
AT coyotemaestaswillow fullspectrumofoct1slc22a1mutationsbridgestransporterbiophysicstodrugpharmacogenomics